Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
Cursiefen
S
S
Department of Neurology, University of Würzburg, Germany.
Flachenecker
P
P
Toyka
K V
KV
Rieckmann
P
P
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology; D009460:Neurologic Examination / Q000187:drug effects; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D008942:Mitoxantrone